Literature DB >> 25536644

Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration.

Rosa Zampino1, Maria A Pisaturo2, Grazia Cirillo3, Aldo Marrone1, Margherita Macera4, Luca Rinaldi1, Maria Stanzione4, Emanuele Durante-Mangoni5, Ivan Gentile6, Evangelista Sagnelli2, Giuseppe Signoriello2, Emanuele Miraglia Del Giudice3, Luigi E Adinolfi1, Nicola Coppola2.   

Abstract

Hepatocellular carcinoma (HCC) is a development of severe liver disease frequently due to HBV and/or HCV infection. The aim of this retrospective study was to evaluate the development of HCC in patients with HBV-HCV chronic infection compared with patients with single HBV or HCV infection and the viral and host factors correlated to HCC in co-infected patients. We studied 268 patients with histology proven chronic hepatitis: 56 had HBV-HCV co-infection (HBV-HCV group), 46 had HBV infection (HBV group) and 166 had HCV infection (HCV group). Patients were followed up for at least 3 years. Viral and host factors were studied. HCC was more frequent in HBV-HCV group (14%) compared with HBV (2%, p = 0.006) and HCV monoinfected (4%, p = 0.006). The Mantel-Haenszel test used to investigate the relationship between HBV-HCV co-infection and development of HCC indicated an association between development of HCC and HBV-HCV co-infection (p < 0.001). In the HBV-HCV group, patients with HCC were significantly older (p = 0.000), had longer disease duration (p = 0.001), higher blood glucose levels (p = 0.001), lower levels of steatosis (p = 0.02), higher levels of fibrosis (p = 0.000), higher HCV RNA (p = 0.01) than those without HCC. ALT, lipid profile, PNPLA3 variant distribution and HBV viral load did not differ among co-infected patients with or without HCC. In conclusion HCC was more frequent in our patients with HBV-HCV co-infection, than in those with HBV or HCV mono-infection; possible associated risk factors for HCC development seem a long duration of disease, high levels of fibrosis and carbohydrate intolerance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25536644

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  17 in total

1.  Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.

Authors:  Luca Rinaldi; Maria Guarino; Alessandro Perrella; Pia Clara Pafundi; Giovanna Valente; Luca Fontanella; Riccardo Nevola; Barbara Guerrera; Natalina Iuliano; Michele Imparato; Alessio Trabucco; Ferdinando Carlo Sasso; Filomena Morisco; Antonio Ascione; Guido Piai; Luigi Elio Adinolfi
Journal:  Dig Dis Sci       Date:  2019-04-01       Impact factor: 3.199

2.  Potential biomarkers of HCC based on gene expression and DNA methylation profiles.

Authors:  Chao Meng; Xiaomin Shen; Wentao Jiang
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

3.  Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.

Authors:  Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

Review 4.  Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways.

Authors:  Luqing Zhao; Yitao Mao; Jianhua Zhou; Yuelong Zhao; Ya Cao; Xiang Chen
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection.

Authors:  Shuhui Liu; Kaitao Zhao; Xi Su; Xiaoxiao Gao; Yongxuan Yao; Ranran Kong; Yun Wang; Chunchen Wu; Mengji Lu; Xinwen Chen; Rongjuan Pei
Journal:  Virol Sin       Date:  2022-05-03       Impact factor: 6.947

Review 6.  Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma.

Authors:  Massimiliano Berretta; Luca Rinaldi; Fabrizio Di Benedetto; Arben Lleshi; Vallì De Re; Gaetano Facchini; Paolo De Paoli; Raffaele Di Francia
Journal:  Front Pharmacol       Date:  2016-11-09       Impact factor: 5.810

7.  PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease.

Authors:  Habeeb Salameh; Maen Masadeh; Muhannad Al Hanayneh; Vincent Petros; Matthew Maslonka; Arjun Nanda; Ashwani K Singal
Journal:  World J Hepatol       Date:  2016-12-18

8.  The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients.

Authors:  Bo Zhou; Chaoyang Sun; Jia Huang; Meng Xia; Ensong Guo; Na Li; Hao Lu; Wanying Shan; Yifan Wu; Yuan Li; Xiaoyan Xu; Danhui Weng; Li Meng; Junbo Hu; Qinglei Gao; Ding Ma; Gang Chen
Journal:  Sci Rep       Date:  2019-02-08       Impact factor: 4.379

9.  Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation.

Authors:  Gang Hu; Shusen Zhai; Sheng Yu; Zhen Huang; Ran Gao
Journal:  Infect Agent Cancer       Date:  2021-06-29       Impact factor: 2.965

10.  Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives.

Authors:  Hanan Hassan Omar
Journal:  Hepat Med       Date:  2019-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.